Gong, Grace Q;
Vanhaesebroeck, Bart;
(2024)
Precision Targeting of Mutant PI3Kα.
Cancer Discovery
, 14
(2)
pp. 204-207.
10.1158/2159-8290.cd-23-1392.
![[thumbnail of 317629_0_merged_1701887950-submitted MS.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
317629_0_merged_1701887950-submitted MS.pdf - Accepted Version Access restricted to UCL open access staff until 9 February 2025. Download (1MB) |
Abstract
PIK3CA, which encodes the p110α catalytic subunit of PI 3-kinase alpha (PI3Kα), is one of the most frequently genetically activated kinases in solid tumors. In two back-to-back papers, Varkaris and colleagues report on the development of a novel allosteric PI3Kα-mutant–selective inhibitor and early clinical experience with this compound. See related article by Varkaris et al., p. 227 (6) . See related article by Varkaris et al., p. 240 (5) .
| Type: | Article |
|---|---|
| Title: | Precision Targeting of Mutant PI3Kα |
| DOI: | 10.1158/2159-8290.cd-23-1392 |
| Publisher version: | http://dx.doi.org/10.1158/2159-8290.cd-23-1392 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10187005 |
Archive Staff Only
 |
View Item |
